SMC (Single Molecule Counting) driving innovative high sensitivity biomarker discovery and detection
Early detection of low level disease biomarkers in research models and clinical samples can translate to the discovery and development of early therapeutic intervention in patients. SMC™ technology provides precise measurement of molecules at levels previously undetectable, leading to unprecedented biomarker insight to fuel discovery of diseases. Huntingtin's and cardiovascular disease are two examples that will be presented.
Dr. Jens Baron - Protein Specialist - Immunoassay Platform Solutions